This is a US news story, published by BBC, that relates primarily to Donanemab news.
For more US news, you can click here:
more US newsFor more Donanemab news, you can click here:
more Donanemab newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from BBC, you can click here:
more news from BBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
dementia medicines. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Alzheimer news, dementia research news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Breakthrough AlzheimerBBC
•Health
Health
87% Informative
Donanemab and lecanemab are the first drugs to slow Alzheimer's disease.
They help the body clear a gungy protein that builds up in the brains of people with the disease.
The drugs could cost 1.5bn a year for the drugs alone.
The official price in the US is 20,000-25,000 per patient per year.
Both pharmaceutical companies involved say they will appeal against the decision.
VR Score
92
Informative language
93
Neutral language
69
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links
